Published in Invest New Drugs on April 18, 2007
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs (2007) 0.83
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.60
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res (2005) 1.55
The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med (1999) 1.39
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer (1992) 1.37
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer (1996) 1.03
The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci U S A (2005) 1.03
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood (2005) 0.95
Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac. Blood (2002) 0.93
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol (1994) 0.90
Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol (2004) 0.90
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer (1999) 0.89
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother Pharmacol (2006) 0.84
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res (2008) 2.27
Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol (2010) 2.10
Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg (2012) 2.05
Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther (2010) 1.94
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood (2002) 1.84
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res (2006) 1.79
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol (2013) 1.57
Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination. Leuk Lymphoma (2008) 1.54
The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing. Hum Mutat (2015) 1.46
Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg (2002) 1.44
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res (2009) 1.43
Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene (2002) 1.37
The fluorometric microculture cytotoxicity assay. Nat Protoc (2008) 1.36
Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Res (2007) 1.36
Cyclotides: a novel type of cytotoxic agents. Mol Cancer Ther (2002) 1.32
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem (2008) 1.32
Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci (2011) 1.30
Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells. Anticancer Drugs (2010) 1.25
Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes (2007) 1.24
Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood (2005) 1.22
Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A (2003) 1.19
Cytotoxic cyclotides from Viola tricolor. J Nat Prod (2004) 1.18
Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts. J Biomol Screen (2002) 1.18
C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol (2002) 1.13
Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer (2012) 1.13
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol (2006) 1.12
Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci U S A (2003) 1.11
Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs. Bioorg Med Chem (2007) 1.11
High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation. Mol Cell Proteomics (2009) 1.10
STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer (2007) 1.09
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol (2009) 1.08
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. J Nat Prod (2009) 1.07
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer (2006) 1.07
Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res (2012) 1.06
Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis (2003) 1.03
Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer. Anticancer Res (2014) 1.02
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol (2006) 1.02
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells. Biochem Biophys Res Commun (2013) 1.01
Polyglutamine repeat length-dependent proteolysis of huntingtin. Neurobiol Dis (2002) 1.00
Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer (2013) 1.00
Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer (2004) 0.99
Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system. Int J Cancer (2009) 0.98
Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol (2011) 0.96
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther (2004) 0.96
Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol (2002) 0.96
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood (2005) 0.95
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies. Med Oncol (2008) 0.94
A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res (2002) 0.94
Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol (2006) 0.93
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol (2013) 0.93
(+)-agelasine D: improved synthesis and evaluation of antibacterial and cytotoxic activities. J Nat Prod (2006) 0.91
Evaluation of the blood compatibility of materials, cells, and tissues: basic concepts, test models, and practical guidelines. Adv Exp Med Biol (2013) 0.90
The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death. Mol Pharmacol (2014) 0.90
Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxid Redox Signal (2013) 0.90
Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol (2012) 0.89
Towards high-throughput single cell/clone cultivation and analysis. Electrophoresis (2008) 0.89
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol (2008) 0.89
Image-based screening for the identification of novel proteasome inhibitors. J Biomol Screen (2007) 0.89
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol (2003) 0.89
Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties. Chem Biol Drug Des (2011) 0.88
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drugs (2004) 0.88
Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. Anticancer Res (2007) 0.88
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett (2004) 0.88
Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res (2006) 0.87
Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Sci (2011) 0.87
Single-tube nested quantitative PCR: a rational and sensitive technique for detection of retroviral DNA. Application to RERV-H/HRV-5 and confirmation of its rabbit origin. J Virol Methods (2003) 0.86
Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol (2003) 0.86